title: Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants.
abstract: Allogeneic bone marrow (BM) transplant (BMT) outcomes have been correlated with the infused nucleated, CD34(+), and T- cell dose. The potential impact of natural killer (NK) BM infused cell dose has however not been established. We analysed the outcomes of 78 patients receiving an HLA identical BMT. A higher NK cell dose was associated with the speed of neutrophil (P = 0.05) and platelet recovery (P = 0.04). Higher nucleated cells, CD34(+), CD3(+), CD3(+)/4(+), CD3(+)/8(+) and NK cell dose were associated with a lower incidence of chronic GvHD (cGvHD) in univariate analysis. In multivariate analysis, the risk of cGvHD was increased by a lower NK cell dose [hazard ratio (HR) = 2.3 (1.2-4.4) for cell dose <0.9 x 10(6)/kg; P = 0.01] and an older age [HR = 1.4 /10 years (1.1-1.8); P = 0.002]. In addition, a higher CD3(+)/4(+) and NK cell dose were associated with a decreased incidence of viral infections (P = 0.03 and P = 0.06 respectively). No specific cell subpopulation infused dose was associated with survival. In conclusion, a higher BM NK cell dose is associated with an increased speed of neutrophil recovery and a decreased incidence of cGvHD.
authors.affiliation: Cell Therapy Unit, Assistance Publique-Hôpitaux de Paris, Saint Louis Hospital, Paris, France.
authors.forename: Jerome
authors.initials: J
authors.lastname: Larghero
authors.forename: Vanderson
authors.initials: V
authors.lastname: Rocha
authors.forename: Raphael
authors.initials: R
authors.lastname: Porcher
authors.forename: Alain
authors.initials: A
authors.lastname: Filion
authors.forename: Brigitte
authors.initials: B
authors.lastname: Ternaux
authors.forename: Marie-Noelle
authors.initials: MN
authors.lastname: Lacassagne
authors.forename: Marie
authors.initials: M
authors.lastname: Robin
authors.forename: Regis
authors.initials: R
authors.lastname: Peffault de Latour
authors.forename: Agnes
authors.initials: A
authors.lastname: Devergie
authors.forename: Nicole
authors.initials: N
authors.lastname: Biscay
authors.forename: Patricia
authors.initials: P
authors.lastname: Ribaud
authors.forename: Marc
authors.initials: M
authors.lastname: Benbunan
authors.forename: Eliane
authors.initials: E
authors.lastname: Gluckman
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Marolleau
authors.forename: Gerard
authors.initials: G
authors.lastname: Socié
mesh_terms: D000328:Adult; D001424:Bacterial Infections / Q000150:complications; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002908:Chronic Disease; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006086:Graft vs Host Disease; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology*; D007958:Leukocyte Count; D008297:Male; D009181:Mycoses / Q000150:complications; D009504:Neutrophils / Q000276:immunology*; D016016:Proportional Hazards Models; D014185:Transplantation, Isogeneic; D014777:Virus Diseases / Q000150:complications